Literature DB >> 17988987

Uneventful cesarean delivery with administration of factor XI concentrate in a patient with severe factor XI deficiency.

Georgios Mavromatidis1, Konstantinos Dinas, Dimitrios Delkos, Fotios Goutzioulis, Christos Vosnakis, Emmanouel Hatzipantelis, Vassilia Garipidou, David Rousso.   

Abstract

Factor XI (FXI) is a procoagulant factor and antifibrinolytic agent, and its absence causes a bleeding tendency. FXI deficiency is autosomal in inheritance, with severe FXI deficiency in homozygotes and partial deficiency in heterozygotes. A 24-year-old primigravida with an uneventful pregnancy and no history of bleeding manifestations was admitted to our department at 38 weeks of gestation. Her blood count and serum biochemistry findings were normal except for a coagulation screen, which revealed a prolonged activated partial thromboplastin time (APTT) of 63 seconds (normal range, 24-35 seconds). The measured FXI coagulant activity of 8 IU/dL (reference range, 70-150 IU/dL) established a diagnosis of severe FXI deficiency. The breech presentation of the fetus prompted the decision for cesarean delivery under general anesthesia. We administered a single dose of FXI concentrate (15 IU/kg), which corrected the APTT to 34 seconds. The cesarean delivery was uncomplicated, and postpartum recovery of the mother and her baby was uneventful with no bleeding complications. The finding of an isolated prolonged APTT should prompt obstetricians to consider FXI deficiency. The appropriate use of factor FXI concentrate in managing obstetric patients with FXI deficiency can minimize potential bleeding complications and ensure an optimal outcome for both mother and neonate.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17988987     DOI: 10.1532/IJH97.E0731

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  35 in total

1.  Secondary postpartum haemorrhage: incidence, morbidity and current management.

Authors:  F Hoveyda; I Z MacKenzie
Journal:  BJOG       Date:  2001-09       Impact factor: 6.531

2.  New hemophilia-like disease caused by deficiency of a third plasma thromboplastin factor.

Authors:  R L ROSENTHAL; O H DRESKIN; N ROSENTHAL
Journal:  Proc Soc Exp Biol Med       Date:  1953-01

3.  What dose of recombinant activated factor VII should be used in patients with factor XI deficiency?

Authors:  S A Brown
Journal:  Haemophilia       Date:  2005-07       Impact factor: 4.287

4.  Production and therapeutic use of a factor XI concentrate from plasma.

Authors:  P H Bolton-Maggs; R T Wensley; P B Kernoff; C K Kasper; L Winkelman; R S Lane; J K Smith
Journal:  Thromb Haemost       Date:  1992-03-02       Impact factor: 5.249

5.  Ultrasonic evaluation of the postpartum uterus in the management of postpartum bleeding.

Authors:  C Y Lee; B Madrazo; B H Drukker
Journal:  Obstet Gynecol       Date:  1981-08       Impact factor: 7.661

6.  High gene frequency of factor XI (PTA) deficiency in Ashkenazi Jews.

Authors:  U Seligsohn
Journal:  Blood       Date:  1978-06       Impact factor: 22.113

7.  Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces.

Authors:  K Naito; K Fujikawa
Journal:  J Biol Chem       Date:  1991-04-25       Impact factor: 5.157

Review 8.  Factor XI deficiency in women.

Authors:  R A Kadir; D L Economides; C A Lee
Journal:  Am J Hematol       Date:  1999-01       Impact factor: 10.047

Review 9.  Inherited bleeding disorders.

Authors:  V S Blanchette; C Sparling; C Turner
Journal:  Baillieres Clin Haematol       Date:  1991-04

10.  Definition of the bleeding tendency in factor XI-deficient kindreds--a clinical and laboratory study.

Authors:  P H Bolton-Maggs; D A Patterson; R T Wensley; E G Tuddenham
Journal:  Thromb Haemost       Date:  1995-02       Impact factor: 5.249

View more
  1 in total

1.  Obstetric outcomes and acceptance of alternative therapies to blood transfusion by Jehovah's Witnesses in Japan: a single-center study.

Authors:  Mie Tanaka; Shinya Matsuzaki; Masayuki Endo; Aiko Kakigano; Kazuya Mimura; Tsuyoshi Takiuchi; Tatsuya Miyake; Takuji Tomimatsu; Yutaka Ueda; Tadashi Kimura
Journal:  Int J Hematol       Date:  2018-06-29       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.